إسرائيل - العبرية - Ministry of Health

sanofi - aventis israel ltd - cabazitaxel 60 mg / 1.5 ml - concentrate for solution for infusion - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen

إسرائيل - العبرية - Ministry of Health

sanofi - aventis israel ltd - cabazitaxel 60 mg / 1.5 ml - concentrate for solution for infusion - cabazitaxel - in combination with prednisone for the treatment of patients with metastatic hormone refractory prostate cancer (mhrpc) previously treated with a docetaxel-based treatment regimen

إسرائيل - العبرية - Ministry of Health

"סיגמא בי.די בע""מ" - רופא - בלון כלילי להרחבת הצרויות עורקים + בלון קטטר המפריש פקליטקסול

إسرائيل - العبرية - Ministry of Health

ביוטים טכנולוגיות בע"מ - רופא - בלון משחרר תרופה להצרויות בכלי דם פריפריים

إسرائيل - العبرية - Ministry of Health

roche pharmaceuticals (israel) ltd - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg/ml - bevacizumab - bevacizumab - avastin in combination with fluoropyrimidine-based chemotherapy is indicated for treatment of patients with metastatic carcinoma of the colon or rectum.avastin in addition to platinum - based chemotherapy is indicated for first - line treatment of patients with unresectable advanced metastatic or recurrent non- small cell lung cancer other than predominantly squamous cell histology. avastin in combination with interferon alfa-2a is indicated for first line treatment of patients with advanced and /or metastatic renal cell cancer. avastin in combination with paclitaxel is indicated for first-line treatment of patients with metastatic breast cancer.avastin as asingle agent, is indicated for the treatment of glioblastoma in patients with progressive disease following prior therapy.avastin, in combination with carboplatin and paclitaxel, is indicated for the front-line treatment of advanced (figo stages iii b, iii c and iv) epithelial ovarian, fallopian tube, or primary peritoneal cancer in patients who are at hig

إسرائيل - العبرية - Ministry of Health

j-c health care ltd - doxorubicin hydrochloride - liposome for infusion - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin - doxorubicin - first or second line therapy of aids related kaposis sarcoma in patients with low cd 4 counts and extensive mucocutaneous or visceral disease the treatment of patients with metastatic carcinoma of the ovary who are refractory to both paclitaxel and platinium-based chemotherapy regimens and who may also be refractory to topotecan. refractory is defined as a patient having progressive disease while on treatment or within 6 months of completing treatmnt. as monotherapy for patients with metastatic breast cancer where there is an increased cardiac risk. in combination with bortezomib for the treatment of progressive multiplemyeloma in patients who have received at least one prior therapy and who have already undergone or are unsuitable for bone marrow transplant.

إسرائيل - العبرية - Ministry of Health

amgen europe b.v. - bevacizumab - תרכיז להכנת תמיסה לאינפוזיה - bevacizumab 25 mg / 1 ml - bevacizumab

إسرائيل - العبرية - Ministry of Health

medison pharma ltd - doxorubicin hydrochloride - אבקה, מפזר וממס להכנת תרכיז לפיזור באינפוזיה - doxorubicin hydrochloride 50 mg vials - doxorubicin - doxorubicin - myocet, in combination with cyclophosphamide, is indicated for the first line treatment of metastatic breast cancer in women.

إسرائيل - العبرية - Ministry of Health

j-c health care ltd - doxorubicin hydrochloride - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin

إسرائيل - العبرية - Ministry of Health

baxter healthcare distribution ltd., israel - doxorubicin hydrochloride - doxorubicin hydrochloride 2.0 mg/ml - doxorubicin